307
Participants
Start Date
December 7, 2020
Primary Completion Date
June 15, 2023
Study Completion Date
December 31, 2025
Arm A - Olaparib
"300 mg orally twice daily, for a total daily dose of 600mg~Study treatment can be dose-reduced to :~First step : 250 mg twice daily , for a total daily dose of 500 mg Second step: 200 mg twice daily taken twice daily, for a total daily dose of 400 mg No further dose reduction is allowed, and study treatment should be discontinued."
ARM B - durvalumab plus selumetinib
"Durvalumab administered IV at a flat dose of 1500 mg on day 1 of every 28-day cycle, Selumetinib Starting Dose : 75 mg twice daily~Study treatment can be dose-reduced to :~Dose Level -1 : 75 mg once daily Dose Level -2 : 50 mg twice daily Dose Level -3 : 50 mg once daily"
ARM C FOLFIRI
FOLFIRI every two weeks Irinotecan 180 mg/m2 Intravenous (IV) on day 1 Folinic acid 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV bolus on day 1 and 2, and 46h IV infusion of 5-FU 2400 mg/m2
Institut Sainte Catherine, Avignon
CHRU Jean Minjoz, Besançon
Polyclinique Bordeaux Nord Aquitaine, Bordeaux
Centre François Baclesse, Caen
Hôpital Beaujon, Clichy
GHPSO Site de Creil, Creil
Centre Georges François Leclerc, Dijon
CHU Dijon, Dijon
CHU Grenoble Alpes Hôpital Michallon, Grenoble
Hôpital Franco-Britannique, Levallois-Perret
CHRU Lille, Lille
centre Léon Bérard, Lyon
Hôpital Privé Jean Mermoz, Lyon
Hôpital Saint Joseph Saint Luc, Lyon
CHU La Timone, Marseille
Hôpital Européen, Marseille
Institut Paoli Calmette, Marseille
Hôpital Nord Franche Comté, Montbéliard
GH Diaconesses Croix Saint Simon, Paris
Hôpital Européen Georges Pompidou, Paris
Hôpital Pitié Salpêtrière, Paris
Hôpital Saint Antoine, Paris
Institut Mutualiste Montsouris, Paris
CHU Poitiers, Poitiers
CHU Robert Debré, Reims
ICO Site de Saint Herblain, Saint-Herblain
Centre Paul Strauss, Strasbourg
CHU Toulouse IUCT Rangueil, Toulouse
Hôpital Trousseau, Tours
Collaborators (1)
AstraZeneca
INDUSTRY
GERCOR - Multidisciplinary Oncology Cooperative Group
OTHER